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A B S T R A C T
Long noncoding (lnc)RNAs have emerged as essential mediators of cellular biology, diﬀerentiation and malig-
nant transformation. LncRNAs have a broad range of possible functions at the transcriptional, posttranscriptional
and protein level and their aberrant expression signiﬁcantly contributes to the hallmarks of cancer cell biology.
In addition, their high tissue- and cell-type speciﬁcity makes lncRNAs especially interesting as biomarkers,
prognostic factors or speciﬁc therapeutic targets. Here, we review current knowledge on lncRNA expression
changes during normal B-cell development, indicating essential functions in the diﬀerentiation process. In ad-
dition we address lncRNA deregulation in B-cell malignancies, the putative prognostic value of this as well as the
molecular functions of multiple deregulated lncRNAs. Altogether, the discussed work indicates major roles for
lncRNAs in normal and malignant B cells aﬀecting oncogenic pathways as well as the response to common
therapeutics.
1. Introduction
It is less than a decade ago that a genome wide long noncoding (lnc)
RNA transcript expression proﬁle has been reported for the ﬁrst time
(Cabili et al., 2011). Current annotations suggest the presence of 15,000
(GENCODE 26) to 60,000 (Iyer et al., 2015) lncRNA genes in the human
genome. The majority of the lncRNAs (70%) are poorly conserved
across species, i.e. they arose in the past 50 million years of evolution
(Guttman et al., 2009; Hezroni et al., 2015). Only a few lncRNAs show
high sequence conservation across species, e.g. XIST, PVT1, MIAT,
NEAT1, MALAT1 and OIP5-AS (Ulitsky, 2016). Globally, lncRNA genes
show higher sequence conservation than randomly selected genomic
regions, this includes positional conservation as well as conservation of
promoter regions, splice sites or the act of transcription itself (reviewed
in (Ulitsky, 2016)). The biological signiﬁcance of lncRNAs was proven
in a murine knockout study in which developmental defects and leth-
ality occurred upon deletion of several lncRNAs (Sauvageau et al.,
2013). A recent large-scale lncRNA knockout screening in human cell
lines identiﬁed for 50 out of 700 lncRNAs tested a signiﬁcant eﬀect on
cancer cell growth (Zhu et al., 2016). Thus, although the functional
signiﬁcance of the bulk of lncRNAs is unclear, a signiﬁcant proportion
of them have major biological functions.
LncRNAs may be transcribed from (eRNAs) or they may share a
promoter with the neighboring coding gene (bidirectional). Despite
having a similar architecture as mRNAs including being subject to
splicing, polyadenlylation and 5’ capping, lncRNAs show characteristics
that clearly distinguish them from mRNAs, such as a generally lower
expression, a fewer number of exons and a much higher tissue speci-
ﬁcity (Iyer et al., 2015; Derrien et al., 2012). The functional repertoire
of lncRNAs appears to be broad, likely owing to their ability to interact
with DNA, RNA and proteins or combinations thereof. Well described
mechanisms include: (i) the modulation of three dimensional chromatin
structure (e.g. Firre) (Hacisuleyman et al., 2014), (ii) scaﬀolding
functions for proteins (e.g. MALAT1, NEAT1) (Hutchinson et al., 2007;
Mao et al., 2011; Clemson et al., 2009), (iii) transcriptional gene reg-
ulation via interaction with DNA and/or proteins including epigenetic
regulators (e.g. HOTAIR) (Rinn et al., 2007) and transcriptional (co)
factors (e.g. lincRNA-p21, GAS5) (Bao et al., 2015; Dimitrova et al.,
2014; Kino et al., 2010), and (iv) posttranscriptional regulation af-
fecting the stability of mRNAs or proteins (e.g. PVT1, GAS5) (Tseng
et al., 2014; Hu et al., 2014) or competing with miRNA binding
(competing endogenous RNAs, ceRNAs (Salmena et al., 2011); e.g. G-
AS5-miR-21) (Zhang et al., 2013).
In solid cancers, lncRNAs have been shown to contribute to all
known cancer hallmarks, i.e. viability, proliferation, growth suppres-
sion, motility, immortality and angiogenesis (reviewed in (Schmitt
et al., 2016)). LncRNA BCAR4 represents an excellent example of a
lncRNA regulating gene expression through direct and indirect eﬀects.
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Mechanistically, BCAR4 directly interacts with the transcription factors
SNIP1 and PNUTS (Xing et al., 2014). The interaction of BCAR4 with
SNIP1 releases its inhibitory eﬀects on p300 histone acetylase, thereby
causing increased H3K18 acetylation at migration-speciﬁc target gene
loci. BCAR4 bound PNUTS then interacts with the acetylated histones to
induce the transcriptional machinery via activation of PP1 phosphatase.
High BCAR4 expression thus results in increased cell motility which is
in line with the correlation of high BCAR4 expression with advanced,
metastatic breast cancer (Xing et al., 2014). Cancer cells may also be-
come addicted to the expression of oncogenic lncRNAs. The melanoma-
speciﬁc lncRNA SAMMSON is an example of a lncRNA excerting its
function by binding to a protein and inﬂuencing its subcellular locali-
zation (Leucci et al., 2016). Mechanistically, SAMMSON increased mi-
tochondrial metabolism by direct binding to p32, resulting in its mi-
tochondrial localization (Leucci et al., 2016). Depletion of SAMMSON
strongly decreased the viability of melanoma cells independently of
mutational status (Leucci et al., 2016).
In recent years much progress has been made regarding the ex-
pression pattern of lncRNAs during diﬀerent stages of B-cell develop-
ment and in diverse B-cell derived malignancies. However, in contrast
to solid cancers, a limited number of studies have addressed the con-
sequences of deregulated lncRNA expression in B-cell malignancies.
Here we provide an overview of the current knowledge on lncRNA
expression changes in normal and malignant B cells, their potential
clinical value as well as their molecular functions.
2. LncRNA expression in normal B cells
Multiple studies have analyzed lncRNA expression patterns in dif-
ferent stages of B-cell development in human (Bonnal et al., 2015;
Casero et al., 2015; Petri et al., 2015; Ranzani et al., 2015; Tayari et al.,
2016) and mouse (Brazao et al., 2016). In general, marked lncRNA
expression changes were observed during B-cell development and ma-
turation. Consequently, B-cell subsets can readily be distinguished
using their lncRNA expression patterns. Transcriptome sequencing of
ten T-cell and three B-cell subsets (Ranzani et al., 2015) showed that
expression of individual lncRNAs is more often restricted to a single
subset (71% of 4764 lncRNAs) than expression of protein coding genes
(35% of 15,911 coding genes) or membrane proteins, which are com-
monly used for subset classiﬁcation (40% of 1051 membrane proteins).
Of note, lncRNAs that showed the highest cell-type speciﬁcity appeared
to be absent in whole lymphoid tissue or peripheral blood mononuclear
cells (PBMCs) likely due to dilution of cell-type speciﬁc lncRNA tran-
scripts in such heterogeneous cell samples (Ranzani et al., 2015). This is
also reﬂected by the fact that studies assessing lncRNA expression
patterns in speciﬁc B-cell subsets (Bonnal et al., 2015; Casero et al.,
2015; Ranzani et al., 2015; Brazao et al., 2016) led to the identiﬁcation
of a large number of previously unannotated transcripts. In contrast to
mRNA expression patterns, lncRNA expression patterns can distinguish
cells committed to the B and T cell lineage already at the progenitor
stage in bone marrow (Casero et al., 2015), indicating their importance
in lineage commitment. At later stages of B-cell development and ma-
turation lncRNA expression proﬁles can be highly similar between
functionally distinct B cells such as follicular and marginal zone B cells
in spleen (Brazao et al., 2016) and naïve and memory cells in tonsils
(Tayari et al., 2016). However, the strongly proliferative germinal
center (GC) B cells showed a lncRNA proﬁle that is very distinctive from
other mature B-cell subsets (Casero et al., 2015; Tayari et al., 2016;
Brazao et al., 2016).
To identify lncRNAs associated with cell fate-related genes at dif-
ferent B-cell development stages, a guilt-by-association analysis was
done on 11 distinct B-cell subsets(Petri et al., 2015). Early B-cell de-
velopment speciﬁc genes, expressed in preBI, preBII and immature B
cells, such as RAG2, VPREB1, DNTT, LEF1, SMAD1 and MYB, were
associated with LEF1-AS1, SMAD1-AS1, MYB-AS1 antisense transcripts,
as well as with the intergenic transcript CTC-436K13.6. Mitotic cell
cycle related genes such as KIF23, PLK4 and CENPE were speciﬁc for
the proliferative stages of B-cell development, i.e. preBI, preBII, cen-
troblasts and centrocytes, and associated with the lncRNAs OIP5-AS,
MME-AS1 and the bidirectional lncRNA CRNDE. CRNDE has previously
been linked to cell cycle and proliferation (Esposti et al., 2016; Song
et al., 2016; Meng et al., 2017; Shao et al., 2016). Expression of AID and
SERPINA9, two genes speciﬁcally expressed in GC centroblasts and
centrocytes, was associated with PVT1 and multiple uncharacterized
lincRNAs, e.g. LINC00487, LINC00877, RP11-203B7.2 and RP11-
132N15.3. The latter one is located 240 kb upstream of BCL6. RNA-seq
of 11 murine B-cell subsets revealed 4516 diﬀerentially expressed
lncRNAs (Brazao et al., 2016). Assessment of the histone H3K4 mono/
trimethylation ratio of these diﬀerentially expressed lncRNAs revealed
192 promoter (high H3K4me3) and 702 enhancer (high H3K4me1)
associated lncRNAs (eRNAs). Comparison with previous human studies
(Bonnal et al., 2015; Casero et al., 2015; Petri et al., 2015) identiﬁed
228 eRNAs with a potential human ortholog based on positional con-
servation and 185 based on sequence conservation. Of note, the above-
mentioned GC B cell associated lncRNA RP11-132N15.3 located
downstream of BCL6 (Petri et al., 2015) has a murine ortholog showing
both sequence and positional conservation. However, this lncRNA ap-
pears to be downregulated in murine GC B cells (Brazao et al., 2016),
while being upregulated in human GC B cells (Petri et al., 2015), in-
dicating that despite strong similarities a functional conservation is
unlikely.
Thus, although most current studies are limited by inclusion of a
restricted number of B-cell subsets (Bonnal et al., 2015; Casero et al.,
2015; Petri et al., 2015; Tayari et al., 2016) or the use of microarrays
preventing the identiﬁcation of novel transcripts (Petri et al., 2015;
Tayari et al., 2016), they provide a valuable overview of B-cell subset
speciﬁc lncRNAs. Now, the ﬁeld is open for studies that establish their
roles in normal B-cell development.
3. Aberrant lncRNA expression in malignant B cells
LncRNA expression proﬁling studies in B-cell malignancies have
been focused on classical Hodgkin lymphoma (cHL), diﬀuse large b-cell
lymphoma (DLBCL), Burkitt lymphoma (BL) and around the tran-
scription factor MYC. Comparison of lncRNA expression patterns of cHL
cell lines to sorted GC B cells from healthy individuals (Tayari et al.,
2016) revealed a total of 475 diﬀerentially expressed lncRNAs. The
majority of them (74%) were downregulated, which may in part be a
reﬂection of the lower degree of heterogeneity in cell lines compared to
sorted B-cell subsets. In line with this, DLBCL cell lines also had a
markedly lower number of expressed lncRNAs compared to sorted
normal B cells and patient cases (Verma et al., 2015).
Re-analysis of RNA-seq data of 116 DLBCL cases, 30 DLBCL cell
lines, 4 naïve and 4 GC B cell subsets (Verma et al., 2015) revealed
2632 novel, multi-exonic lncRNAs. For approximately half of these,
expression was restricted to DLBCL cases or to both DLBCL cases and
cell lines. DLBCL cases display high heterogeneity in clinical behavior,
mRNA expression and genomic aberrations (Karmali and Gordon,
2017) and this is also reﬂected in their lncRNA expression proﬁles, as
most tumor-speciﬁc lncRNAs were found in only small subsets of cases
(Verma et al., 2015). Interestingly, among the lncRNAs with increased
levels in a subset of the DLBCL cases, 33 were located in recurrently
ampliﬁed genomic regions, supporting a potential role for these
lncRNAs in the pathogenesis of DLBCL. To further establish a relation
between the identiﬁed lncRNAs and DLBCL biology, their co-expression
with the transcriptional repressors BCL6 and EZH2, a component of the
polycomb repressive complex 2 (PRC2), was assessed. A signiﬁcant
negative correlation with BCL6 or EZH2 expression was found for 323
and 431 lncRNAs, respectively. A signiﬁcant proportion of these
(> 40%) were also induced by EZH2 or BCL6 depletion, supporting the
hypothesis that at least part of these lncRNAs are BLC6 or PRC2 target
genes. Globally, the study showed that lncRNAs are an intrinsic part of
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tight regulatory networks in DLBCL; expression of 88% of the novel
lncRNAs correlated signiﬁcantly with at least one protein-coding gene
(Verma et al., 2015). Unfortunately, the study was restricted to newly
identiﬁed lncRNAs and excluded> 8000 previously annotated
lncRNAs. A total of 465 novel lncRNAs could readily distinguish acti-
vated B cell (ABC) and germinal center B cell (GCB) DLBCL subtypes in
unsupervised hierarchical clustering (Verma et al., 2015). As expected
these lncRNAs did not show any overlap with the 156 annotated ABC/
GCB speciﬁc lncRNAs identiﬁed in another study (Zhou et al., 2017). A
subset of 17 of these 156 subtype speciﬁc lncRNAs was suﬃcient to
distinguish the ABC and GCB subtypes with a speciﬁcity and sensitivity
of approximately 90% and accordingly predicted treatment outcome
(Zhou et al., 2017). CRNDE and MME-AS1, shown to be highly ex-
pressed in GC B cells (Petri et al., 2015), were among the lncRNAs with
a signiﬁcantly higher expression level in the GCB subtype DLBCL (Zhou
et al., 2017). Other studies analyzed expression diﬀerences in DLBCL
for selected lncRNA candidates based on known functions or altered
expression in other cancer types. These studies identiﬁed increased le-
vels of HOTAIR (Yan et al., 2016), HULC (Peng et al., 2016) and
LUNAR1 (Peng and Feng, 2016) and decreased levels of lincRNA-p21
(Peng et al., 2017) in DLBCL tissues. Lastly, MALAT1 levels were in-
creased in eight DLBCL cell lines compared to Epstein-Barr virus (EBV)-
transformed lymhoblastoid cells (Li et al., 2017).
LncRNAs regulated by the well-known transcription factor MYC
may have prevalent roles in the mediation of oncogenic MYC-induced
eﬀects. In two studies, the P493-6 B cell line carrying a tetracycline-
repressible MYC allele was used to identify MYC-regulated lncRNAs.
Using microarray and RNAseq these studies identiﬁed>1200 (Winkle
et al., 2015) and 534 (Hart et al., 2014) MYC-regulated lncRNAs. Re-
analysis of these RNAseq data (Hart et al., 2014) by another group
increased the number of MYC-regulated lncRNAs to 960 (Doose et al.,
2015). In each study approximately half of the lncRNA loci were MYC-
induced and the other half were MYC-repressed, similar to the pattern
observed for protein coding mRNAs (Winkle et al., 2015). The com-
parison of MYC occupancy at MYC-responsive lncRNA and mRNA loci
revealed an intriguing diﬀerence. Both, MYC-induced and -repressed
lncRNAs were enriched for MYC binding sites, while only the MYC-
induced mRNAs showed enriched of MYC binding sites (Winkle et al.,
2015). For mRNAs, this is in line with the hypothesis that MYC tends to
further upregulate transcripts already active in a speciﬁc cell type (Lin
et al., 2012; Nie et al., 2012). However, downregulated lncRNAs also
seem to be actively repressed by MYC (Winkle et al., 2015). In a
comparison of primary lymphoma cases with low (CLL) and high MYC
levels (BL) the expected MYC-regulated pattern was observed for 54%
of the diﬀerentially expressed lncRNAs (Winkle et al., 2015). Of the
lncRNAs signiﬁcantly up- or downregulated in BL cases compared to
normal GC B cells (514 and 367 lncRNAs, respectively), 27% were
identiﬁed as MYC-regulated lncRNAs (Doose et al., 2015). Further
overlap of these lncRNAs with lncRNAs regulated in the hT-RPE-MycER
model (retinal pigment epithelial cell line with MYC-ER fusion gene)
deﬁned a limited set of 13 common MYC-regulated lncRNAs. This small
overlap is likely due to the diﬀerence in cell types, in line with previous
reports describing a limited set of cell type common ‘core’ MYC target
genes in the coding genome (Ji et al., 2011). One of these lncRNAs,
termed MINCR (MYC-induced noncoding RNA), showed a signiﬁcant
correlation with MYC expression in BL cases as well as in MYC trans-
location positive DLBCL and FL cases (Doose et al., 2015). No clear
correlation with MYC expression was observed in normal tissues or BL
cell lines (Hart et al., 2016). MINCR was also identiﬁed as a MYC-
regulated lncRNA in P493-6 cells (Winkle et al., 2015; Hart et al., 2014)
and shown to have MYC binding sites (Winkle et al., 2015) Other an-
notated lncRNAs deﬁned as MYC-induced based on multiple datasets
(Winkle et al., 2015; Hart et al., 2014) include e.g. GAS5, DANCR,
KTN1-AS1, MCM3AP-AS1 and OIP5-AS. As the speciﬁcity of MYC-reg-
ulation has been under debate (Lin et al., 2012; Nie et al., 2012;
Lorenzin et al., 2016), disabling the nearby MYC binding sites using
CRISPR-Cas9 technology may provide a more deﬁnitive answer on
whether these and other MYC-induced and -repressed lncRNAs are di-
rectly regulated by MYC.
Thus although the number of proﬁling studies is limited, they
clearly show that lncRNA expression patterns are deregulated in lym-
phoma. The candidate lncRNAs derived from these studies provide an
excellent starting point for further studies aiming at identifying their
function or assessing their potential clinical value.
4. LncRNAs with clinical value in B-cell malignancies
Reanalysis of microarray data of> 1000 DLBCL patients revealed a
6 lncRNA signature (Sun et al., 2016) correlating with overall survival
in DLBCL patients in two independent cohorts. High expression of
MME-AS1, CSMD2-AS1, RP11-360F5.1, RP11-25K19.1, CTC-467M3.1
was associated with a favorable outcome, while high expression of
SACS1-AS was associated with poor outcome. The six-lncRNA score
remained a signiﬁcant predictor of overall survival in multivariate
analysis, together with age at diagnosis, lactate dehydrogenase (LDH)
levels and ECOG performance status (Sun et al., 2016). In line with the
better prognosis of GCB DLBCL, the expression levels of MME-AS1,
CSMD2-AS1 and CTC-467M3.1 was enhanced in GCB DLBCL, while
expression of the risk associated lncRNA SACS1-AS was higher in ABC
DLBCL (Zhou et al., 2017). These studies thus show that lncRNA ex-
pression patterns are potentially valuable biomarkers for prognosis.
High levels of MALAT1 in a group of 40 MCL patients predicted
worse overall survival (Wang et al., 2016a). In contrast, a meta-analysis
in multiple myeloma (MM) (n = 144) and DLBCL (n = 200 and 414)
patients indicated a good prognostic potential of high MALAT1 ex-
pression levels (Wang et al., 2016b). Moreover, pre-treatment MALAT1
plasma levels were decreased in MM patients compared to healthy
controls and the decrease was associated with advanced clinical stage
(Isin et al., 2014). However, reduced MALAT1 levels were associated
with a prolonged progression free survival in post-treatment bone
marrow samples of MM patients (Cho et al., 2014). Further adding to
the controversy, high expression levels of MALAT1 in mesenchymal
stem cells present in the tumor microenvironment of MM patients was
shown to be detrimental to disease progression (Li et al., 2014). In
summary, the prognostic potential of MALAT1 remains inconclusive
and requires further study in large patient cohorts using plasma, tumor
cell and tumor microenvironment derived samples.
Low expression levels of lincRNA-p21 was an independent predictor
of poor 5-year OS and PFS in a cohort of 105 DLBCL patients (Peng
et al., 2017). In CLL patients, lincRNA-p21 plasma levels were de-
creased compared to healthy controls and this decrease was associated
with advanced clinical stage (Isin et al., 2014). High HULC (Peng et al.,
2016) and LUNAR1 (Peng and Feng, 2016) expression levels predicted
worse OS and PFS in DLBCL cohorts of 147 and 87 patients, respec-
tively. Furthermore, LUNAR1 is activated by NOTCH1 (Trimarchi et al.,
2014) and the presence of activating NOTCH1 mutations correlated
with worse prognosis in CLL (Puente et al., 2011; Willander et al.,
2013). High HOTAIR expression was shown to be a predictor of worse
OS in 50 DLBCL patients, also as an independent predictor next to high
International Prognostic Index (IPI) scores (Yan et al., 2016). However,
in a DLBCL cohort of 164 cases, high HOTAIR expression levels corre-
lated with better outcome, possibly due to the negative correlation
between HOTAIR and MYC expression (Oh et al., 2016). MIAT ex-
pression was studied in 67 CLL cases (Sattari et al., 2016) and high
expression was more often observed in aggressive types of CLL. Lastly,
plasma levels of the lncRNA TUG1 were signiﬁcantly decreased in MM
and its downregulation correlated with advanced disease state (Isin
et al., 2014).
Thus, lncRNAs are building up potential as valuable tools in the
clinic, e.g. as prognostic indicators and biomarkers for disease.
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5. Molecular functions of lymphoma associated lncRNAs
For multiple lncRNAs deregulated in lymphoma, functional studies
have been performed to shed light on their precise involvement in
cancer cell biology. In this section, we discuss knowledge on the on-
cogenic or tumor suppressive functions of these lncRNAs revolving
around apoptosis and cell growth.
5.1. Apoptotic pathways
Functional FAS signaling is crucial for eﬀective treatment response
in lymphoma patients (Friesen et al., 1996; Friesen et al., 1999). Sen-
sitivity to FAS ligands is regulated through alternative splicing, pro-
ducing either the membrane bound FAS receptor (mFAS) or a soluble
decoy receptor (sFAS). LncRNA FAS-AS1 was shown to be crucially
involved in regulating this process by acting as a decoy for RNA binding
motif protein 5 (RBM5), a protein that promotes the alternative splicing
to sFAS (Fig. 1A, top). Thus, high FAS-AS1 levels inhibit alternative
splicing of the FAS transcript and thus the production of sFAS (Sehgal
et al., 2014). In lymphoma cells, FAS-AS1 expression levels were de-
creased due to polycomb repressive complex 2 (PRC2)-mediated his-
tone methylation. As a consequence sFAS levels increase preventing
FAS-ligand induced apoptosis (Fig. 1A, bottom). Inhibition of EZH2, the
catalytic component of PRC2, using DZNep resulted in de-repression of
FAS-AS1 and sensitized lymphoma cells to FAS-mediated apoptosis by
upregulation of mFAS. The BTK inhibitor ibrutinib similarly increased
FAS-AS1 levels and apoptosis through downregulation of EZH2 and
RBM5 transcript levels (Sehgal et al., 2014).
LincRNA-p21 (∼17 kb upstream of p21) and NEAT1 were identiﬁed
as p53-responsive transcripts by analyzing expression levels in primary
CLL cells with functional (p53WT) and disrupted p53 signaling (p53mut/
del or ATMdel) (Blume et al., 2015). Upon p53 stimulation both lncRNA
loci showed increased expression and occupancy by p53 in p53WT CLL
cells, but not in p53mut/del cells and ATMdel cells. LincRNA-p21 and
NEAT1 aﬀect diﬀerent p53-mediated processes, i.e. inducing apoptosis
or cell cycle arrest and DNA repair (Fig. 1B). Three independent studies
showed a direct interaction of lincRNA-p21 with heterogeneous nuclear
ribonucleoprotein K (hnRNP-K) in murine embryonic ﬁbroblasts (MEFs)
(Bao et al., 2015; Dimitrova et al., 2014; Huarte et al., 2010). hnRNP-K
is a transcriptional co-factor thought to act in apoptosis induction via
p53-dependent gene repression (Kim et al., 2008), a process less well-
characterized than p53-mediated gene activation. Furthermore, hnRNP-
K was shown to assist p53 recruitment to the p21 promoter (Moumen
et al., 2005), thus supporting cell cycle checkpoint integrity. In vitro
lincRNA-p21 knockdown in MEFs caused activation of many p53-re-
pressed target genes and decreased apoptotic levels, without aﬀecting
p21 (Huarte et al., 2010). However, conditional knockout of lincRNA-
p21 in murine embryonic ﬁbroblasts (MEFs) diminished p21 levels
thereby causing checkpoint defects and increased proliferation, while
no changes in apoptosis were observed (Dimitrova et al., 2014). In line
with a cis-induced p21 activation by lincRNA-p21, its expression posi-
tively correlated with p21 levels across 34 CLL cases (Blume et al.,
2015). In contrast to the proposed cis eﬀect of lncRNA-p21 on p21
(Dimitrova et al., 2014) it was shown that ectopic expression of
lncRNA-p21 in a DLBCL cell line caused an increase in p21 and G1 cell
cycle arrest (Peng et al., 2017). To assess feasibility of therapeutic
targeting of lincRNA-p21, it is important to study which downstream
p53-responses are aﬀected in B cells and whether low lincRNA-p21
levels are solely caused by p53 mutations or also by epigenetic or (post-
) transcriptional mechanisms. The p53-induced lncRNA NEAT1 was
shown to take part in the p53-induced DNA repair response pathway
(Adriaens et al., 2016). Opposed to its role in apoptosis induction, the
Fig. 1. LncRNAs involved in apoptotic pathways. (A) LncRNA FAS-AS1 is required for eﬃcient FAS-FASL-induced apoptotic signaling. In normal cells FAS-AS1 is expressed (top), acting as
a decoy for RNA binding motif protein 5 (RBM5). This prevents interaction of RBM5 with FAS pre-mRNA and leads to production of membrane-bound FAS (mFAS) and eﬀective triggering
of apoptosis upon binding to the FAS ligand. In lymphoma cells (bottom), FAS-AS1 transcription is shut down by polycomb repressive complex 2 (PRC2) enabling interaction of RBM5 with
FAS pre-mRNA, which mediates exon 6 exclusion, leading to production of soluble (s)FAS and inhibition of apoptosis. DZNep and ibrutinib can both re-activate FAS-AS1 expression and
sensitize cells to apoptosis. (B) Functional mechanisms of p53-induced lincRNA-p21 (red) and NEAT1 (blue). Interaction of LincRNA-p21 with heterogeneous nuclear ribonucleoprotein K
(hnRNP-k) results in (1) downregulation of p53-repressed target genes in trans, thereby inducing apoptosis and (2) enhances p21 transcription in cis, resulting in G0/G1 cell cycle arrest.
NEAT1 (blue) is essential for the formation of nuclear paraspeckles, which leads to activation of ATR signaling and thereby activates G2/M and inter-S phase checkpoints and promotes
DNA repair. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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DNA repair response triggered by p53 may support cell survival and
hamper the eﬀects of genotoxic and p53-reactivation therapeutics. The
formation of paraspeckles (i.e. nuclear substructures involved in RNA
metabolism/translation regulation) is induced by replication stress and
dependent on p53 activation as well as NEAT1 expression (Clemson
et al., 2009; Adriaens et al., 2016). Interestingly, depletion of NEAT1 in
cancer cell lines sensitized them to replication stress-inducing agents
such as genomycin, doxorubicin and PARP inhibitors. Mechanistically,
NEAT1 depletion compromised activation of DNA repair-promoting
ATR signaling (Adriaens et al., 2016). Inhibition of ATR signaling in
CLL and MCL cells that strongly depend on this pathway (i.e. ATMmut
cells) increased chemosensitivity (Kwok et al., 2015; Menezes et al.,
2015). Future work should address the precise role of NEAT1 in p53
and ATR signaling in normal and malignant B cells.
Knockdown of the lncRNA HULC in a DLBCL cell line resulted in
increased apoptosis via downregulation of the anti-apoptotic BCL2
protein (Peng et al., 2016). HULC was previously shown to protect from
apoptosis through direct repression of the tumor suppressor EEF1E1
(P18/AIMP3), and subsequent prevention of the DNA-damage induced
activation of p53 (Du et al., 2012; Zhao et al., 2015).
5.2. Proliferation and growth
HOTAIR acts as a cofactor in PRC2-mediated repression via induc-
tion of H3K27me3 at speciﬁc gene loci (Rinn et al., 2007). Multiple
lines of evidence suggest an important oncogenic role for PRC2 in
lymphoma (reviewed in (Lund et al., 2014)): (1) The presence of re-
current activating EZH2 (i.e. the catalytic component of PRC2) muta-
tions in GCB DLBCL, FL and BL leading to a global increase in
H3K27me3 levels (Morin et al., 2010; Yap et al., 2011; Lunning and
Green, 2015); (2) the association of high EZH2 and H3K27me3 levels
with aggressive clinicopathological features in both ABC and GCB
DLBCL (Oh et al., 2014; Zhou et al., 2015); and (3) accelerated MYC-
driven lymphomagenesis by EZH2 activating mutations (Berg et al.,
2014). In addition, increased HOTAIR expression has been observed in
23% of DLBCL cases (n = 164) and positively correlated with high
EZH2 expression, but not with global H3K27me3 levels (Oh et al.,
2014). This was used as an argument to support a speciﬁc rather than a
global manner of H3K27me3 regulation by HOTAIR in DLBCL. Inter-
estingly, increased HOTAIR correlated with low MYC levels (Oh et al.,
2014). As MYC was previously shown to indirectly repress genes, in-
cluding its own transcription, via EZH2 (Kaur and Cole, 2013) it is
intriguing to speculate that HOTAIR may be involved in this auto-
regulatory process. Another study suggested an oncogenic role for
HOTAIR in DLBCL by activation of NF-kB and phosphorylation of PI3K
and AKT (Yan et al., 2016). Activation of NF-kB by HOTAIR was also
described in murine cardiac muscle cell lines (Wu et al., 2016). All
together these data support an important role for HOTAIR in the pa-
thogenesis of lymphoma.
GAS5 was discovered as a transcript speciﬁcally expressed in
growth-arrested cells (Schneider et al., 1988) and was shown to induce
growth arrest in normal T lymphocytes (Mourtada-Maarabouni et al.,
2008). Its expression is tightly regulated by mTOR, where high mTOR
levels (i.e. growing cells) shut down GAS5 expression post-tran-
scriptionally (Smith and Steitz, 1998). mTOR signaling plays pivotal
roles in B-cell diﬀerentiation (Xu et al., 2012) and the pathway is ac-
tivated in B-cell malignancies (Karmali and Gordon, 2017; Limon and
Fruman, 2012). Depletion of GAS5 in MCL cell lines and leukemic T
cells inhibits the apoptotic response to multiple therapeutic compounds
(Pickard and Williams, 2015), such as mTOR antagonists (Mourtada-
Maarabouni and Williams, 2014) and dexamethasone (Mourtada-
Maarabouni et al., 2008). The various molecular mechanisms described
for GAS5 (Fig. 2) (reviewed in (Pickard and Williams, 2015)) are in line
with its broad eﬀects on cell growth: (1) GAS5 knockdown increased
levels of CDK6, a protein involved in G1/S transition, thereby causing a
more rapid cell cycle and increased proliferation (Liu et al., 2013; Lu
et al., 2013); (2) GAS5 acts as a decoy for the glucocorticoid receptor,
preventing transcription of target genes including the apoptosis in-
hibitors cIAP2 and SGK1 (Kino et al., 2010); (3) GAS5 downregulates
miR-21, a known oncomiR in B-cell lymphoma (Medina et al., 2010),
and miR-21 targets GAS5, thus forming a reciprocal feedback loop
(Zhang et al., 2013), and (4) GAS5 downregulates MYC at the transla-
tional level via interaction with the translation initiation factor 4E
(eIF4E) (Hu et al., 2014). The reported induction of GAS5 by MYC
(Winkle et al., 2015; Hart et al., 2014) could indicate presence of a
negative feedback loop to regulate MYC levels (Fig. 3). These studies
showed that GAS5 is a potent tumor suppressor lncRNA acting as a
master regulator of growth and apoptosis in B-cell lymphoma.
PVT1 (located downstream of MYC) has been implicated in B-cell
Fig. 2. GAS5 mediates growth arrest. In proliferating cells, GAS5 is repressed by active
mTOR, miR-21 and DNA methylation. In growth arrested cells, GAS5 levels are increased
and negatively inﬂuence growth and apoptosis associated genes, such as MYC, CDK6 (G1-
to-S transition), cIAP2 and SGK1 (anti-apoptotic) as well as known oncomiR microRNA-
21. GcR – glucocorticoid receptor.
Fig. 3. LncRNAs in the MYC pathway. Diﬀerent lncRNAs were implied in the regulation
of MYC at the transcriptional (HOTAIR), translational (GAS5) and protein (PVT1) level. In
addition, miR-1204 encoded within the PVT1 transcript may induce MYC indirectly. The
MYC-induced MINCR lncRNA aﬀects proliferation through regulation of cell cycle genes.
Several MYC-responsive lncRNAs are likely involved in the MYC-induced eﬀects on
proliferation, de-diﬀerentiation and apoptosis.
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lymphoma based on the association of several SNP alleles within the
PVT1 locus with the risk on FL (Skibola et al., 2014), DLBCL (Bassig
et al., 2015) and cHL (Enciso-Mora et al., 2010a). In addition, PVT1 is
co-translocated with MYC to the immunoglobulin locus in many BL
cases (Zeidler et al., 1994) and in part of the DLBCL cases (Tsutsumi
et al., 2013). In MM, translocations of the PVT1 locus to non-im-
munoglobulin loci have been observed in 58% (7 of 12) of MM cases
and 63% of MM cell lines (5 of 8) with 8q24 abnormalities (Nagoshi
et al., 2012). In addition, PVT1 is frequently co-ampliﬁed in cancers
with MYC copy number increase. In mice, ampliﬁcation of a larger
genomic region (i.e. Myc, Pvt1, Ccdc26 and Gsdmc) caused a greatly
decreased tumor latency time compared to ampliﬁcation of MYC alone
(Tseng et al., 2014). Functional studies in other cancer types have re-
vealed three possible modes of action for PVT1 (reviewed in (Colombo
et al., 2015; Cui et al., 2016)) (Fig. 3). First, PVT1 is the host gene for
the miR-1204-1208 cluster and miR-1204 was found to be upregulated
in B and T cells that highly express PVT1 (Huppi et al., 2008; Beck-
Engeser et al., 2008). Ectopic expression of murine miR-1204 indirectly
increased MYC levels in pre-B, but not in pro-B cells (Huppi et al.,
2008). Second, PVT1 was shown to interfere with MYC phosphorylation
at threonine 58, a modiﬁcation that promotes MYC degradation (Tseng
et al., 2014). This may result in a positive feedback mechanism, as
PVT1 is induced by MYC (Winkle et al., 2015; Carramusa et al., 2007).
Third, PVT1 was shown to be induced by TGF-β signaling, resulting in
increased proliferation as well as further upregulation of TGF-β. This
eﬀect was dependent on the interaction of PVT1 with proliferation-as-
sociated protein NOP2 resulting in its stabilization (Wang et al., 2014).
TGF-β signaling in non-Hodgkin lymphoma cells may lead to exhaus-
tion of the T-cell eﬀector response through upregulation of CD70 (Yang
et al., 2014).
Knockdown of the MYC-regulated lncRNA MINCR caused a partial
G0/G1 cell cycle arrest in hT-RPE-MycER cells (Doose et al., 2015).
RNAseq analysis upon MINCR depletion revealed downregulation of a
signiﬁcant number of genes involved in cell cycle regulation. Several of
these genes were directly regulated by MYC and their knockdown
phenocopied the eﬀects of MINCR knockdown in BL cells (Doose et al.,
2015). These data suggest that MINCR positively regulates MYC
binding to promotor regions of important cell cycle regulators. The
MINCR knockdown-induced eﬀect on cell cycle arrest was observed in
both MYC high and MYC low cells, suggesting that MINCR also med-
iates MYC-independent eﬀects. MINCR knockdown aﬀected a total of
1227 genes (Doose et al., 2015), suggesting a much broader function of
this lncRNA (Fig. 3).
LUNAR1 was ﬁrst described as a NOTCH1-induced lncRNA in T-
ALL. The NOTCH1 enhancer element of LUNAR1 is located in the last
intron of the downstream IGF1R gene (Trimarchi et al., 2014). LUNAR1
was shown to positively regulate expression of IGF1R in cis. Accord-
ingly, LUNAR1 depletion decreased cell viability in T-ALL cell lines,
while ectopic IGF1R re-expression restored normal growth. This in-
dicates that LUNAR1 mainly functions through the IGF1R pathway
(Trimarchi et al., 2014). Aberrant expression of both NOTCH1 (Wein
et al., 2015) and IGF1R (Liang et al., 2014) has been reported in cHL
although LUNAR1 was not expressed in HL cell lines (Tayari et al.,
2016). LUNAR1 was expressed in DLBCL cases (Peng and Feng, 2016),
but not in primary CLL or BL cases (Winkle et al., 2015). In DLBCL
increased LUNAR1 levels were linked to cell cycle progression (Peng
and Feng, 2016). As inhibition of IGF1R in T-ALL (Trimarchi et al.,
2014) and DLBCL (Stromberg et al., 2015) cell lines decreased cell
viability, it would be interesting to determine whether LUNAR1 is in-
volved in this phenotype.
MALAT1 is a proliferation and metastasis-inducing oncogene in-
volved in many solid cancers (reviewed in (Yoshimoto et al., 2016)).
MALAT1 has broad functions and acts through regulation of tran-
scription and alternative splicing (Yoshimoto et al., 2016). Although
high MALAT1 expression is described as a good prognostic factor in
DLBCL patients (Wang et al., 2016a), its knockdown in DLBCL cell lines
lead to decreased viability (Li et al., 2017). Speciﬁcally, MALAT1
knockdown caused increased apoptosis, cell cycle arrest and autophagy
(Li et al., 2017). Mesenchymal stem cells (MSCs) of MM patients con-
sistently showed increased MALAT1 expression compared to MSCs of
normal controls (Li et al., 2014). This was proposed to support tumor
cell survival and bone destruction by regulating TGF-β bioavailability.
This was achieved by interaction of MALAT1 with the SP1 transcription
factor, which induced expression of LTBP3 (ca. 30 kb downstream of
MALAT1) in cis (Li et al., 2014). LTBP3 regulates the bioavailability of
TGF-β in the extracellular environment (Dabovic et al., 2002). Ac-
cordingly, MALAT1 levels strongly correlated with both LTBP3 and
TGF-β levels in MM patient-derived MSCs (Li et al., 2014). Thus, this
study is the ﬁrst to reveal a signiﬁcant role of lncRNA overexpression in
the MSCs present in the microenvironment of the MM cells.
6. Conclusions and future perspectives
Clearly, evidence is accumulating that lncRNAs are signiﬁcantly
involved in B-cell development, lymphomagenesis and lymphoma cell
biology. Their high cell type speciﬁc expression patterns makes them
potentially novel biomarkers for diﬀerent clinical applications in the
coming years. In addition, modulation of lncRNAs might improve
therapy response, for example by modulating FAS-AS1 levels through
inhibition of EZH2 using DZNep or ibrutinib (Adriaens et al., 2016),
and modulating GAS5 levels using demethylating agents (Khamas et al.,
2012; Shi et al., 2015). In relation to novel or improved therapeutic
approaches, lncRNAs situated in the p53 pathway or in the MYC
pathway are also of particular interest.
Besides the above-discussed studies there are also other lines of
evidence that point towards important roles for lncRNAs in lympho-
magenesis. Firstly, GWAS studies revealed associations for SNPs within
chromosomal regions referred to as ‘gene deserts’. Such SNPs may be
associated with the functionality of lncRNAs as shown in a recent study
linking 26% of investigated disease associated SNPs (n = 11,194) to
lncRNA genes (Iyer et al., 2015). The most evident lymphoma asso-
ciated SNPs are located in the PVT1 locus at 8q24 (Skibola et al., 2014;
Bassig et al., 2015; Cerhan et al., 2014; Enciso-Mora et al., 2010b;
Crowther-Swanepoel et al., 2010). Secondly, the act of lncRNA tran-
scription has recently been connected to recurrent genomic transloca-
tions introduced by AID and RAG1 involved in lymphomagenesis (af-
fecting e.g. MYC, BCL-6, BCL-2). Speciﬁcally, it was shown that
recurrent AID translocation hotspots are situated in genomic regions
where convergent sense mRNA and antisense lncRNA transcription
occurs (Meng et al., 2014; Qian et al., 2014). The antisense transcrip-
tion was initiated from gene-overlapping super-enhancers. Notably,
such convergent transcription also occurrs at the PVT1 locus (Meng
et al., 2014; Qian et al., 2014; Klein et al., 2011), possibly explaining its
frequent involvement in genomic rearrangements in B cells (Zeidler
et al., 1994; Tsutsumi et al., 2013; Nagoshi et al., 2012). In addition, the
lncRNA RP11-211G3.3.1-1 transcribed antisense of intron 1 of the BCL6
gene was shown to encompass the exact chromosomal breakpoint re-
gion in> 87% of primary DLBCL cases (Lu et al., 2015). The GAS5
locus was also found to be amongst the AID-induced translocation
hotspots (Klein et al., 2011). In a single DLBLC case the ﬁrst exons of
GAS5 were fused to the BCL6 gene, which resulted in increased BCL6
expression (Nakamura et al., 2008). Whether AID is responsible for
translocations between diﬀerent AID oﬀ-target (i.e. non-Ig) genes re-
quires further investigation. Lastly, RAG1-induced breakpoints in pre-B-
ALL were also enriched in enhancer regions showing convergent tran-
scription (Heinaniemi et al., 2016). Thus, these studies support a sig-
niﬁcant role for lncRNA transcription in genome integrity in B cells.
A major factor hampering current lncRNA research is their limited
evolutionary conservation (Ulitsky, 2016), which greatly restricts the
use of available animal models to study their functions. In line with this,
the best characterized lncRNAs are the most conserved ones, such as
MALAT1, NEAT1, XIST and PVT1. In this respect, it would be of interest
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to study the role of OIP5-AS in lymphoma as this lncRNA is conserved
even in zebraﬁsh (called ‘cyrano’). Its high expression observed in
proliferating B cells (Petri et al., 2015), as well as its induction by MYC
(Winkle et al., 2015; Hart et al., 2014) are typical features of pro-
liferation-associated lncRNAs. Notably, OIP5-AS was shown to act as a
sponge for HuR (Kim et al., 2008), a RNA-binding protein that plays an
essential role in B-cell development (Diaz-Munoz et al., 2015) and
regulates MYC (Mihailovich et al., 2015). The study of less conserved
lncRNAs calls for the use of primary cells, humanized animal or primate
models to improve our insights into their functions and interactions in
vivo.
In the past decade vast advancements have been made regarding the
toolbox for lncRNA research. Novel techniques such as global run-on
(GRO)-sequencing (Gardini, 2017) give a detailed picture of nascent
RNA transcription. In addition, lncRNA annotation databases are con-
stantly growing (e.g. Broad institute human lincRNA catalog, LNCi-
pedia) (Cabili et al., 2011; Volders et al., 2013), and ensure the in-
tegration of lncRNAs into systems biology, e.g. by assessment of co-
expression networks with known proteins. In this regard, it is of utmost
importance that raw as well as analyzed lncRNA expression datasets are
made publically available to allow cross-comparisons. As lncRNA
transcription is often directly linked to their functionality, the use of
technologies such as CRISPR-Cas9 or antisense oligonucleotides (ASOs)
to achieve (co-)transcriptional knockdown should be preferred over
conventional RNAi methods. LncRNA-protein interactions may be stu-
died using either conventional protein-IP or novel lncRNA-IP techni-
ques (e.g. ChIRP, CHART, RAP) (Chu et al., 2012; Davis and West,
2015; Engreitz et al., 2014). Lastly, RNA-FISH technology has been
developed to visualize single lncRNA molecules in living cells (Cabili
et al., 2015).
In conclusion, lncRNAs are quickly advancing as main players in the
pathogenesis of B-cell malignancies. Some lncRNAs show potential as
therapeutic (co-)targets, particularly those that are actively involved in
the mediation of chemotherapeutic eﬀects. To this end, eﬀorts are made
to develop small molecule inhibitors that speciﬁcally disrupt lncRNA-
protein interactions (Pedram Fatemi et al., 2015). Furthermore, as an-
tisense oligonucleotide-based therapies gradually make their way to the
clinic (Adams et al., 2017), new ways to therapeutically target speciﬁc
lncRNAs seem just a grasp away.
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